Summary
The current drug development research paradigm is flawed in that it fails to include a diverse and representative patient population. A new approach that begins with a patient-centric mindset, coupled with the use of mobile technology and connected health platforms, will enable research to become less reliant on site-based visits and bring equal access to new investigational therapies for all patients, regardless of geography, ethnicity, sex, or gender.
In this white paper, you will learn about:
- The current diversity gap and limitations in clinical research
- Barriers for underrepresented patient populations
- Breaking barriers with patient-centric approaches and advanced technology
- Foundations for a new clinical research model
- Engaging and protecting patients with technology
Register to download
Bridging the Diversity Gap with Decentralized Trials
You may also be interested in:
Blog
COVID-19 Kicks Healthcare Technology Adaptation into High Gear
From telemedicine to decentralized clinical trials to artificial intelligence and beyond, the COVID-19 crisis has kicked the use of technology in the…
Publication
Three Necessary Steps When Designing your New World Protocol
This article explores the design of a protocol that includes decentralized components. After a clinical-trial protocol has been developed, adding…
Page
PRA’s Mobile Health Platform
PRA’s Mobile Health Platform (MHP) engages with patients wherever they are. Our app-based platform allows us to do everything that’s possible in a…